C+77/100
Desk Score
Dispatch #8Editorial
Henry Meds
A flat-fee compounded pioneer — simple model, but now priced at the higher end of the market.
Visit Henry Meds ↗Editorial — no commercial relationship.
- Semaglutide
- $249/mo
- Tirzepatide
- $349/mo
- Coverage
- Multi-state
- Brand-name
- Compounded only
Desk Score breakdown
Each of the six scored dimensions. See the methodology.
Price transparency70/100
State access80/100
Molecule range82/100
Onboarding speed76/100
Support responsiveness78/100
Licensing & trust80/100
What the Desk likes
- Simple flat-fee model with known pricing
- Established brand recognition
- Both molecules offered
Where points come off
- Higher pricing than newer market entrants
- Multi-state only, not all 50
- Compounded only
The Desk's briefing — C+
Best for: People who want a simple, well-known flat-fee brand without complexity.
Pricing and verification reflect Henry Meds's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on Henry Meds's site. Not medical advice; see our disclosure.